MARK2 and neoplasm: This molecular targeted agent can inhibit the proliferation of tumor cells by inhibiting the Raf serine/threonine kinases as well as inhibit tumor angiogenesis by inhibiting the receptor tyrosine kinase activity of Vascular Endothelial Growth Factor(VEGFF) receptors (VEGFRs) 2 and 3, which lays the theoretical foundation of combining TACE therapy and sorafenib together [14–17].